Long-term patterns of adherence to medication therapy among patients with type 2 diabetes mellitus in Denmark: The importance of initiation

PLoS One. 2017 Jun 30;12(6):e0179546. doi: 10.1371/journal.pone.0179546. eCollection 2017.

Abstract

Aims: Poor adherence to medication therapy among type 2 diabetes patients is a clinical challenge. We aimed to determine which factors are associated with the three phases of long-term adherence to medication: initiation, implementation and discontinuation in a register-based study.

Methods: Adherence to six medicine groups (metformin, sulfonylureas, acetylsalicylic acid, thiazide diuretics, renin angiotensin system inhibitors, and statins) were analysed among 5,232 patients with type 2 diabetes at a tertiary referral hospital during 1998-2009. Rate-ratios of initiation of treatment, recurrent gaps in supply of medication, and discontinuation of treatment were analysed using Poisson regression.

Results: Poor initiation rather than poor implementation or discontinuation was the main contributor to medication nonadherence. Polypharmacy was a risk factor for slower initiation of treatment for all six medicine groups (rate ratio ranging 0.79 95%CI [0.72-0.87] to 0.89 95%CI [0.82-0.96] per already prescribed medicine), but once patients were in treatment, polypharmacy was not associated with recurrence of gaps in supply of medication, and polypharmacy was associated with lower risk of discontinuation (rate ratio ranging 0.93 95%CI [0.86-1.00] to 0.96 95%CI [0.93-0.99] per prescribed medicine). Other identified risk factors for slow initiation, poor implementation, and discontinuation were diabetes duration, younger age, and Turkish/Pakistani origin.

Discussion: This study showed that a risk factor does not necessarily have the same association with all three elements of adherence (initiation, implementation and discontinuation), and that efforts supporting patients introduced to more complex drug combinations should be prioritized.

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use*
  • Denmark
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diuretics / therapeutic use*
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Hypolipidemic Agents / therapeutic use*
  • Male
  • Middle Aged
  • Patient Compliance*

Substances

  • Antihypertensive Agents
  • Diuretics
  • Hypoglycemic Agents
  • Hypolipidemic Agents

Grants and funding

This study received funding from The Danish Agency for Science, Technology and Innovation, Bredgade 40, DK-1260 Copenhagen K Grant number: 11-117460 www.http://innovationsfonden.dk/en, “danmark” sygeforsikring (a mutual health insurance company) www.sygeforsikring.dk M.L.J, M.E.J. and B.C. were employed at Steno Diabetes Center until 31 December 2016, a diabetes research hospital and a teaching center owned by Novo Nordisk A/S, associated with Copenhagen University Hospital, and working in partnership with the health authorities of the Capital Region of Denmark. Steno Diabetes Center A/S received part of its core funding from unrestricted grants from the Novo Nordisk Foundation and Novo Nordisk A/S. M.L.J., M.E.J. and B.C. own shares in Novo Nordisk A/S. No one at the Novo Nordisk Foundation or at Novo Nordisk A/S had any role in study design, data collection and analysis, decisions to publish, or preparation of the manuscript. Steno Diabetes Center provided support in the form of salaries for authors [M.L.J, M.E.J. and B.C.], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.